Does insurance cover Oncotype DX for prostate cancer?
Does insurance cover Oncotype DX for prostate cancer?
FFS Medicare, Medicare Advantage plans, and most private insurance carriers cover the Oncotype DX GPS assay for eligible patients with localized risk prostate cancer. Exact Sciences† is an in-network provider with many health plans, including Aetna, Anthem, Cigna, Humana and UnitedHealthcare.
Is Oncotype DX for prostate cancer accurate?
Specifically, 288 of the 732 genes analyzed, or almost 40%, reliably predicted recurrence; and 198 of 732 (almost 40%) reliably predicted aggressive disease. Based these findings Oncotype DX appears to reliably predict the aggressiveness of prostate cancer at diagnosis.
How much does a decipher test cost?
Several genomics tests for prostate cancer have come on the market in recent years; they include Prolaris, Decipher and Oncotype DX. The tests cost between $3,800 and $5,000 and generally are covered by Medicare and some private insurers, according to reporting by the Wall Street Journal.
How do you detect metastatic prostate cancer?
If your doctor suspects your cancer may have spread beyond your prostate, one or more of the following imaging tests may be recommended:
- Bone scan.
- Ultrasound.
- Computerized tomography (CT) scan.
- Magnetic resonance imaging (MRI)
- Positron emission tomography (PET) scan.
When should I order Oncotype DX?
You may be a candidate for the Oncotype DX Breast Recurrence Score Test if: you’ve recently been diagnosed with stage I, stage II, or stage IIIa invasive breast cancer. the cancer is estrogen-receptor-positive. the cancer is HER2-negative.
What is genomic testing for prostate cancer?
Genomic testing is done on cancerous tissue taken from the prostate in order to provide information about how your prostate cancer might behave. By looking at the genetic makeup of the cancer, these tests may help predict whether your prostate cancer grows slowly or aggressively.
What is the average Oncotype DX score?
The mean Oncotype Dx score was 17.0 ± 9.1; it was 14.1 ± 6.8 for Grade-I tumors; 15.7 ± 7.5 for grade -II tumors; and 23.2 ± 12.3 for grade-III tumors [Mean Oncotype Dx score across Tumor grades was compared by ANOVA (η = 0.121), p < 0.001].
What is the most accurate test for prostate cancer?
If your doctor determines you should undergo screening, he or she will most likely recommend the PSA test. For more than 30 years, the PSA test has been the gold standard in prostate cancer screening. This simple blood test measures how much prostate-specific antigen is in your blood.
How accurate is the decipher test?
The Decipher test was developed to address the need for a reliable biomarker, and retrospective studies that looked back in time have shown that it does indeed outperform standard markers like PSA level. The test looks at the activity of 22 genes in prostate tumors and calculates a score from 0 to 1.
How reliable is the Oncotype DX test?
A large population-based observational study based on the SEER registry of more than 40,000 node-negative and 4,500 node-positive patients who received the Oncotype DX test in clinical settings showed Breast Cancer Specific Mortality (BCSM) at five years was less than half a percent in node negative disease and one …
How does the Oncotype DX genomic prostate score work?
The Oncotype DX Genomic Prostate Score (GPS) assay is the only genomic assay designed for men with clinically low- or intermediate-risk cancer to help make treatment decisions at the time of diagnosis. The assay analyzes prostate cancer gene activity to predict disease aggressiveness.
What is the GPS score for prostate cancer?
Providing a GPS result ranging from 0-100 that corresponds to the biologic aggressiveness of the tumor. Measuring biology through the expression of 17 genes across four important genetic pathways and, in conjunction with clinical risk factors, predicts the likelihood of adverse pathology, prostate cancer death, and metastasis at 10 years. 1
How does genomics work to diagnose prostate cancer?
The assay analyzes prostate cancer gene activity to predict disease aggressiveness. It examines interactions among genes in the tumor to better understand the unique biology of the cancer—a science known as genomics—for prostate cancer patients.